Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Inflammatory Bowel Diseases 2Crohn Disease 2

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 744Bevacizumab 716Cisplatin 708Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 338Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × MEDI2070 × Clear all
NCT01714726 2021-05-26

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

AstraZeneca

Phase 2 Completed
121 enrolled 22 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT02574637 2021-05-26

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

AstraZeneca

Phase 2 Terminated
29 enrolled 25 charts

Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡